| Title: |
Protection of mRNA vaccines against hospitalized COVID-19 in adults over the first year following authorization in the United States |
| Authors: |
Tenforde, Mark W; Self, Wesley H; Zhu, Yuwei; Naioti, Eric A; Gaglani, Manjusha; Ginde, Adit A; Jensen, Kelly; Talbot, H Keipp; Casey, Jonathan D; Mohr, Nicholas M; Zepeski, Anne; McNeal, Tresa; Ghamande, Shekhar; Gibbs, Kevin W; Files, D Clark; Hager, David N; Shehu, Arber; Prekker, Matthew E; Erickson, Heidi L; Gong, Michelle N; Mohamed, Amira; Johnson, Nicholas J; Srinivasan, Vasisht; Steingrub, Jay S; Peltan, Ithan D; Brown, Samuel M; Martin, Emily T; Monto, Arnold S; Khan, Akram; Hough, Catherine L; Busse, Laurence W; ten Lohuis, Caitlin; Duggal, Abhijit; Wilson, Jennifer G; Qadir, Nida; Chang, Steven Y; Mallow, Christopher; Rivas, Carolina; Babcock, Hilary M; Kwon, Jennie H; Exline, Matthew C; Botros, Mena M; Lauring, Adam S; Shapiro, Nathan I; Halasa, Natasha; Chappell, James D; Grijalva, Carlos G; Rice, Todd W; Jones, Ian D; Stubblefield, William B; Baughman, Adrienne; Womack, Kelsey N; Rhoads, Jillian P; Lindsell, Christopher J; Hart, Kimberly W; Turbyfill, Caitlin; Olson, Samantha; Murray, Nancy; Adams, Katherine; Patel, Manish M |
| Source: |
Clinical Infectious Diseases, vol 76, iss 3 |
| Publisher Information: |
eScholarship, University of California |
| Publication Year: |
2023 |
| Collection: |
University of California: eScholarship |
| Subject Terms: |
Clinical Research; Prevention; Immunization; Vaccine Related; Good Health and Well Being; Humans; Middle Aged; COVID-19; COVID-19 Vaccines; Hospitalization; mRNA Vaccines; RNA; Messenger; SARS-CoV-2; United States; Aged; duration of protection; waning; vaccine effectiveness; mRNA; Influenza and Other Viruses in the Acutely Ill (IVY) Network; Biological Sciences; Medical and Health Sciences; Microbiology |
| Description: |
BackgroundCoronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines were authorized in the United States in December 2020. Although vaccine effectiveness (VE) against mild infection declines markedly after several months, limited understanding exists on the long-term durability of protection against COVID-19-associated hospitalization.MethodsCase-control analysis of adults (≥18 years) hospitalized at 21 hospitals in 18 states 11 March-15 December 2021, including COVID-19 case patients and reverse transcriptase-polymerase chain reaction-negative controls. We included adults who were unvaccinated or vaccinated with 2 doses of a mRNA vaccine before the date of illness onset. VE over time was assessed using logistic regression comparing odds of vaccination in cases versus controls, adjusting for confounders. Models included dichotomous time ( |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
unknown |
| Relation: |
qt2kf9s474; https://escholarship.org/uc/item/2kf9s474; https://escholarship.org/content/qt2kf9s474/qt2kf9s474.pdf |
| DOI: |
10.1093/cid/ciac381 |
| Availability: |
https://escholarship.org/uc/item/2kf9s474; https://escholarship.org/content/qt2kf9s474/qt2kf9s474.pdf; https://doi.org/10.1093/cid/ciac381 |
| Rights: |
public |
| Accession Number: |
edsbas.F5680AF3 |
| Database: |
BASE |